cardinal health glp-1 receptor agonist weight management diabetes treatments Long-term Success of GLP-1s Hinges on More Than Just a Prescription GLP-1-directed NMDA receptor antagonism for

Nature (1983) 302:7168

Operations and Global Business Development and President of Novo Nordisk Inc

Bain, S

All three amylin products appear to have the potential to challenge tirzepatide on an efficacy/tolerability basis, so it will be interesting to see how Novo Nordisk and Eli Lilly position these products alongside their current GLP-1 offerings

There was some evidence of publication bias (Egger test, P = 0.94), but the trim-and-fill method indicated that this publication bias did not impact the estimate

5 mg) experienced more gastrointestinal events, although continued treatment generally resulted in lessening of symptoms